- Home
- EDSA vs GOVX Comparison
EDSA vs GOVX Comparison
Compare EDSA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- GOVX
- Stock Information
- Founded
- EDSA 2015
- GOVX 2001
- Country
- EDSA Canada
- GOVX United States
- Employees
- EDSA N/A
- GOVX N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- GOVX Health Care
- Exchange
- EDSA Nasdaq
- GOVX Nasdaq
- Market Cap
- EDSA 13.8M
- GOVX 15.5M
- IPO Year
- EDSA N/A
- GOVX N/A
- Fundamental
- Price
- EDSA $2.03
- GOVX $0.96
- Analyst Decision
- EDSA Strong Buy
- GOVX Strong Buy
- Analyst Count
- EDSA 2
- GOVX 5
- Target Price
- EDSA $13.00
- GOVX $12.40
- AVG Volume (30 Days)
- EDSA 33.4K
- GOVX 1.6M
- Earning Date
- EDSA 08-08-2025
- GOVX 08-05-2025
- Dividend Yield
- EDSA N/A
- GOVX N/A
- EPS Growth
- EDSA N/A
- GOVX N/A
- EPS
- EDSA N/A
- GOVX N/A
- Revenue
- EDSA N/A
- GOVX $5,591,576.00
- Revenue This Year
- EDSA N/A
- GOVX N/A
- Revenue Next Year
- EDSA N/A
- GOVX N/A
- P/E Ratio
- EDSA N/A
- GOVX N/A
- Revenue Growth
- EDSA N/A
- GOVX N/A
- 52 Week Low
- EDSA $1.55
- GOVX $0.73
- 52 Week High
- EDSA $5.59
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- EDSA 52.89
- GOVX 46.22
- Support Level
- EDSA $1.91
- GOVX $0.85
- Resistance Level
- EDSA $2.14
- GOVX $1.39
- Average True Range (ATR)
- EDSA 0.12
- GOVX 0.15
- MACD
- EDSA 0.02
- GOVX -0.02
- Stochastic Oscillator
- EDSA 64.52
- GOVX 18.52
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.